[A26-40] Asciminib (CML, first- and second-line treatment) – Addendum to Project A25-150
Last updated 21.05.2026
Project no.:
A26-40
Commission:
Commission awarded on 08.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)
Result of dossier assessment:
- Patients undergoing first-line treatment: after addendum now: indication of a minor added benefit
- Patients who have previously been treated with a tyrosine kinase inhibitor (TKI); second-line treatment: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-40
| Project no. | Title | Status |
|---|---|---|
| A25-150 | Asciminib (CML, first- and second-line treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
21-05-2026 A G-BA decision was published.
G-BA documents on this decision